drugset
drugset / Trial / NCT00485810

Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia

NCT00485810 ↗

Phase 1/2 Completed 31 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the clinical therapeutic dose in Japanese agitated patients with schizophrenia.

Timeline

Start
2004-06
Primary completion
—
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule — Intramuscular

Indications

schizophrenia